In a patient with Alzheimer’s disease, how should the surface marking of the hippocampal and parahippocampal regions be performed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Surface Marking of Hippocampal and Parahippocampal Regions in Alzheimer's Disease

In patients with Alzheimer's disease, surface marking of the hippocampal and parahippocampal regions should be performed using MRI-based surface morphometry mapping that focuses on the CA1 region, subiculum, and anterior-inferior pole of the entorhinal cortex, as these areas show the earliest and most significant atrophy patterns predictive of AD progression.

Recommended Imaging Approach

MRI head without IV contrast is the primary modality for surface marking and volumetric assessment 1. The 2025 ACR Appropriateness Criteria establishes that brain MRI without contrast can demonstrate regional atrophy patterns that correlate with tau deposition and serve as valid biomarkers for AD 1.

Specific Anatomical Targets for Surface Marking

Hippocampal Subregions (Priority Areas)

  • CA1 region and subiculum: These show the greatest inward deformation in AD converters, with localized atrophy being superior to whole hippocampal volume measurements 2
  • Hippocampal head: Demonstrates predominant atrophy, particularly in early conversion from MCI to AD 2
  • Superior-inferior orientation: Texture analysis aligned with the superior-inferior tract orientation (perforant path fibers through subiculum) shows strongest associations with disease severity 3

Entorhinal Cortex

  • Anterior-inferior pole bilaterally: Shows early and significant involvement, with greater atrophy predicting conversion to AD 2
  • This region demonstrates selective vulnerability before widespread hippocampal changes become apparent

Parahippocampal Regions

  • Parahippocampal gyrus: Shows lesser but measurable deformation compared to hippocampus and entorhinal cortex 2
  • Amygdala: Particularly the basolateral complex shows prominent inward surface deformation 4

Technical Methodology

Surface-Based Morphometry (Preferred)

Fine-grained surface morphometry is superior to simple volumetric assessment for predicting AD conversion 2. The methodology should include:

  • Surface deformation mapping: Captures localized inward deformation representing regional atrophy patterns 2, 4
  • Texture features: Grey-level run-length matrix (GLRLM) metrics, particularly run entropy in the subiculum aligned with superior-inferior fiber orientation 3
  • Multiscale structural mapping (MSSM+): Integrates cortical thickness, grey-white matter contrast, sulcal depth, and cortical curvature 5

Volumetric Measures (Complementary)

While surface morphometry is preferred, volumetric assessment remains clinically useful:

  • Hippocampal volume: Predicts conversion to AD with 80% accuracy, though also seen in older patients without cognitive deficits 1
  • Entorhinal cortex thickness: Used for risk stratification in MCI cohorts 1
  • Total intracranial volume-normalized measurements: For standardized comparisons 6

Critical Technical Considerations

Automated Segmentation Tools

  • HippUnfold or Automatic Segmentation of Hippocampal Subfields: Enables consistent delineation of CA1-3, dentate gyrus, subiculum, and medial temporal cortices 7
  • Quality control is mandatory: Exclude mislabeled or artifact-degraded segmentations 3

Image Processing Requirements

  • Bias-field correction
  • Intensity normalization
  • Appropriate voxel resampling 3
  • High-resolution T2-weighted sequences (e.g., HighResHippo protocol) provide superior subfield delineation 3

Clinical Interpretation Framework

Diagnostic Accuracy

When surface morphometry distances are entered together with corresponding hippocampal or entorhinal cortex volumes in regression models, the surface distances remain highly significant while volumes become marginally significant or non-significant 2. This demonstrates the superior predictive value of localized surface analysis.

Longitudinal Tracking

Surface-based morphometry measures show strongest longitudinal effects in individuals progressing from MCI to AD, where surface geometry changes accompany accelerated volume loss 7. Stable MCI shows minimal SBM changes, while stable AD shows primarily volume loss without significant surface remodeling 7.

Common Pitfalls to Avoid

  1. Relying solely on whole hippocampal volume: This misses critical regional specificity in CA1/subiculum that predicts conversion 2

  2. Ignoring directional components: The superior-inferior orientation aligned with perforant path fibers shows strongest disease associations compared to other directional components 3

  3. Using contrast enhancement: Imaging findings of AD are demonstrated without IV contrast; contrast adds no diagnostic value and unnecessary cost/risk 1

  4. Overlooking quality control: Automated segmentation requires verification to exclude mislabeling, particularly in atrophied structures 3

Integration with Other Biomarkers

Surface marking accuracy improves when combined with:

  • Brain amyloid PET/CT: Increases accuracy of predicting MCI to AD conversion 1
  • CSF tau levels: Higher subicular run entropy correlates with elevated CSF tau 3
  • Cognitive testing: Surface changes differentially associate with domain-specific decline (memory, language, visuospatial) across disease stages 7

References

1
Guideline

acr appropriateness criteria® dementia: 2024 update.

Journal of the American College of Radiology, 2025

Related Questions

What should I tell an 84-year-old patient, as his primary care physician, about MRI findings of no acute intracranial abnormality and mild diffuse brain volume loss?
What tacrolimus trough concentration should be targeted in pediatric patients with type 1 autoimmune hepatitis?
What are the indications for mitral valve repair versus mitral valve replacement?
When should serum osmolality be measured, what is the normal reference range, and how is it interpreted?
Urinalysis shows Trichomonas vaginalis with 60‑70 pus cells per high‑power field; what is the appropriate treatment?
In a 75‑year‑old woman with chronic pain syndrome, gout, prior statin‑related liver enzyme elevation with mild steatosis, cholecystectomy, rheumatoid arthritis previously treated with methotrexate (now stopped) and various biologics, currently taking low‑dose prednisone, esomeprazole, and desloratadine, who recently completed courses of ciprofloxacin and furazolidone for a urinary infection, and who presents with fluctuating but sometimes markedly elevated alanine aminotransferase (ALT), persistently high gamma‑glutamyl transferase (GGT), modestly elevated alkaline phosphatase, low bilirubin, negative hepatitis B and C serology, past hepatitis A and hepatitis E exposure, and a positive antinuclear antibody (ANA), what is the most likely cause of her liver test abnormalities and what management steps should be taken?
Which scalp EEG electrode placements best correlate with hippocampal activity?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.